Corresponding to our results, Pysz et al. reported a significant difference of targeted imaging signal using CEUS and BR55 already 24h after initiation of anti-VEGF-antibody therapy in human colon cancer xenografts in mice, which remained significantly lower in treated than in untreated animals during 5 days of observation [10]. The gene discussed is VEGFA; the disease is colonic neoplasm.